Contribute Try STAT+ Today

A new analysis finds that the clinical trials conducted by Biogen (BIIB) for its controversial Alzheimer’s treatment would have excluded as many as 92% of Medicare beneficiaries — a key portion of the targeted patient population — based on their age or existing medical conditions.

Breaking it down, a total of 92% of patients with Alzheimer’s and related disorders, 91% with Alzheimer’s specifically, and 85.5% with mild cognitive impairment met at least one of the criteria for exclusion from the studies, according to the analysis published in JAMA. The most common criteria were heart disease, conditions associated with blood clots, chronic kidney disease, and an age of 85 years or older. Most people actually met more than two of the criteria used for excluding participants.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment